Evotec SE (EVO) Income from Continuing Operations (2009 - 2025)

Evotec SE (EVO) reported Income from Continuing Operations of 120365220.22 for Q4 2025, up 42.5% on a YoY basis from 84469503.11 in Q4 2024, and down 240274.03% sequentially from 50074.14 in Q3 2025.

Evotec SE (EVO) Income from Continuing Operations (2009 - 2025) Analysis & Trends

Evotec SE (EVO) has 9 years of Income from Continuing Operations data on file, last reported at 120365220.22 in Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 42.5% year-over-year to 120365220.22; the trailing twelve-month figure through Dec 2025 stood at 329789072.46 (down 10.08% YoY), and the FY2025 full-year result was 120498292.51, up 42.49% from the prior year.
  • Income from Continuing Operations declined to 120365220.22 in Q4 2025, from 50074.14 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 246254899.13 in Q4 2021 to a low of 209314347.96 in Q4 2024.
  • A 5-year average of 23523562.29 and a median of 22125.42 in 2022 frame the typical range for Income from Continuing Operations.
  • Across the five-year window, Income from Continuing Operations soared 8771.52% in 2021 and plunged 361.5% in 2024, its largest moves.
  • Tracing EVO's Income from Continuing Operations over 5 years: stood at 246254899.13 in 2021, then sank by 172.83% to 179338481.97 in 2022, then surged by 49.68% to 90236548.48 in 2023, then sank by 131.96% to 209314347.96 in 2024, then surged by 42.5% to 120365220.22 in 2025.
  • Business Quant data shows EVO's Income from Continuing Operations at 120365220.22 in Q4 2025, 50074.14 in Q3 2025, and 209314347.96 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 57.00 Mn
10 Evotec SE 346.06 Mn 345.54 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -120.37 Mn
Sep 30, 2025 -50,074.14
Dec 31, 2024 -209.31 Mn
Sep 30, 2024 -59,430.15
Dec 31, 2023 -90.24 Mn
Sep 30, 2023 22,726.50
Jun 30, 2023 -13,888.14
Dec 31, 2022 -179.34 Mn
Sep 30, 2022 39,779.45
Jun 30, 2022 -22,125.42
Mar 31, 2022 -72,868.90
Dec 31, 2021 246.25 Mn
Sep 30, 2021 160,102.41
Jun 30, 2021 73,489.46
Mar 31, 2021 68,554.02
Dec 31, 2020 7.47 Mn
Sep 30, 2020 1,804.68
Dec 31, 2019 41.30 Mn
Sep 30, 2010 1,282.23
Jun 30, 2010 2,369.92